These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26779407)

  • 1. Targeting translation initiation in breast cancer.
    Akcakanat A; Hong DS; Meric-Bernstam F
    Translation (Austin); 2014; 2(1):e28968. PubMed ID: 26779407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translation initiation in colorectal cancer.
    Parsyan A; Hernández G; Meterissian S
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):387-95. PubMed ID: 22418835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors.
    Larsson O; Li S; Issaenko OA; Avdulov S; Peterson M; Smith K; Bitterman PB; Polunovsky VA
    Cancer Res; 2007 Jul; 67(14):6814-24. PubMed ID: 17638893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer.
    Ochnik AM; Baxter RC
    Endocr Relat Cancer; 2016 Nov; 23(11):R513-R536. PubMed ID: 27733416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of translation initiation as cancer therapeutics.
    Lindqvist L; Pelletier J
    Future Med Chem; 2009 Dec; 1(9):1709-22. PubMed ID: 21425987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.
    Albain KS; Carey L; Gradishar WJ; Gralow JR; Lipton A; Rugo H; Tripathy D; Peck S; Abair T; Pegram M
    Clin Breast Cancer; 2010 Dec; 10(6):421-39. PubMed ID: 21147685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
    Pettersson F; Del Rincon SV; Miller WH
    Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
    Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
    Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment.
    Nwabo Kamdje AH; Seke Etet PF; Vecchio L; Muller JM; Krampera M; Lukong KE
    Cell Signal; 2014 Dec; 26(12):2843-56. PubMed ID: 25093804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation.
    Attar-Schneider O; Zismanov V; Drucker L; Gottfried M
    Tumour Biol; 2016 Apr; 37(4):4755-65. PubMed ID: 26515338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.
    Johnston SR
    Int J Gynecol Cancer; 2006; 16 Suppl 2():543-8. PubMed ID: 17010069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation regulation as a therapeutic target in cancer.
    Grzmil M; Hemmings BA
    Cancer Res; 2012 Aug; 72(16):3891-900. PubMed ID: 22850420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1.
    Fujii T; Yokoyama G; Takahashi H; Toh U; Kage M; Ono M; Shirouzu K; Kuwano M
    Curr Med Chem; 2008; 15(6):528-37. PubMed ID: 18336267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting forkhead box M1 transcription factor in breast cancer.
    O'Regan RM; Nahta R
    Biochem Pharmacol; 2018 Aug; 154():407-413. PubMed ID: 29859987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.